AVBP•benzinga•
B. Riley Securities Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $37
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 20, 2025 by benzinga